Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2016

Open Access 01-12-2016 | Original research

The clinical safety, biodistribution and internal radiation dosimetry of [18F]AH113804 in healthy adult volunteers

Authors: E. J. Somer, R. Owenius, A. Wall, G. Antoni, A. Thibblin, J. Sörensen

Published in: EJNMMI Research | Issue 1/2016

Login to get access

Abstract

Background

Quantitative biodistribution, venous blood and excretion data have been obtained following the intravenous bolus injection of AH113804 (18F) Injection in six healthy volunteers (HVs), four males and two females, up to approximately 5 h post-injection.
For each subject, key organs and tissues were delineated and analytical fits were made to the image data as functions of time to yield the normalised cumulated activities. These were input to an internal radiation dosimetry calculation based upon the Medical Internal Radiation Dose (MIRD) schema for the Cristy-Eckerman adult male or female phantom. The absorbed doses per unit administered activity to the 24 MIRD-specified target organs were evaluated for an assumed 3.5-h urinary bladder voiding interval using the Organ Level INternal Dose Assessment/Exponential Modelling (OLINDA/EXM) code. The sex-specific absorbed doses were then averaged, and the effective dose per unit administered activity was calculated.

Results

Excluding the remaining tissue category, the three source regions with the highest mean initial 18F activity uptake were the liver (18.3%), lung (5.1%) and kidney (4.5%) and the highest mean normalised cumulated activities were the urinary bladder contents and voided urine (1.057 MBq h/MBq), liver (0.129 MBq h/MBq) and kidneys (0.065 MBq h/MBq). The three organs/tissues with the highest mean sex-averaged absorbed doses per unit administered activity were the urinary bladder wall (0.351 mGy/MBq), kidneys (0.052 mGy/MBq) and uterus (0.031 mGy/MBq).

Conclusions

AH113804 (18F) Injection was safe and well tolerated. Although the effective dose, 0.0298 mSv/MBq, is slightly greater than for other common 18F PET imaging radiopharmaceuticals, the biodistribution and radiation dosimetry profile remain favourable for clinical PET imaging.
Literature
1.
Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 2007;213:316–25.CrossRefPubMed
2.
van Scheltinga Terwisscha AGT, Lub-de Hooge MN, Hinner MJ, et al. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. J Nucl Med. 2014;55:665–71.CrossRef
3.
Arulappu A, Battle M, Eisenblaetter M, et al. c-Met PET Imaging Detects early Stage Loco-Regional Recurrence of Basal-Like Breast Cancer. J Nucl Med. 2016;57(5):765-70.
4.
Burggraaf J, Kamerling IMC, Gordon PB, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015;21(8):955–61.CrossRefPubMed
5.
Newbold A, Martin BP, Cullinane C, Bots M. Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in solid tumors. Cold Spring Harb Protoc. 2014. doi:10.​1101/​pdb.​prot082529.
6.
International Commission on Radiological Protection. ICRP publication 89: basic anatomical and physiological data for use in radiological protection: reference values. Oxford: Pergamon; 2003.
7.
Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23.CrossRef
8.
McParland BJ. Nuclear medicine radiation dosimetry: advanced theoretical principles. Berlin: Springer; 2010.CrossRef
9.
Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to fetus from radionuclides in the bladder. Health Phys. 1973;25:147–61.CrossRefPubMed
10.
International Commission on Radiological Protection. ICRP publication 56, part 2: age-dependent doses to members of the general public from intake of radionuclides. Oxford: Pergamon; 1992.
11.
Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine; 1988.
12.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed
13.
Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. Volumes I – VII. Oak Ridge National Laboratory; 1987. Report No.: ORNL/TM-8381
14.
International Commission on Radiological Protection. ICRP publication 103: recommendations of the international commission on radiological protection. Oxford: Pergamon; 2007.
15.
International Commission on Radiological Protection. ICRP publication 60: recommendations of the international commission on radiological protection. Oxford: Pergamon; 1991.
16.
International Commission on Radiological Protection. ICRP publication 80, addendum to ICRP 53: radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon; 1998.
17.
Takikawa S, Dhawan V, Spetsieris P, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology. 1993;188:131–6.CrossRefPubMed
18.
Eberlein U, Bröer JH, Vandevoorde C, et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine—a review. Eur J Nucl Med Imaging. 2011;38:2269–81.CrossRef
19.
International Commission on Radiological Protection. ICRP publication 106: radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon; 2007.
Metadata
Title
The clinical safety, biodistribution and internal radiation dosimetry of [18F]AH113804 in healthy adult volunteers
Authors
E. J. Somer
R. Owenius
A. Wall
G. Antoni
A. Thibblin
J. Sörensen
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2016
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-016-0239-y

Other articles of this Issue 1/2016

EJNMMI Research 1/2016 Go to the issue

Original research

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy

Original research

The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor

Original research

The effect of dimethyl sulfoxide on the induction of DNA strand breaks in plasmid DNA and colony formation of PC Cl3 mammalian cells by alpha-, beta-, and Auger electron emitters 223Ra, 188Re, and 99mTc

Original research

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

Original research

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation

Original research

Effects of acetaminophen on mitochondrial complex I activity in the rat liver and kidney: a PET study with 18F-BCPP-BF